Vontobel Holding Ltd. Has $94.16 Million Position in IDEXX Laboratories, Inc. $IDXX

Vontobel Holding Ltd. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 64.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 147,384 shares of the company’s stock after selling 266,150 shares during the quarter. Vontobel Holding Ltd. owned about 0.18% of IDEXX Laboratories worth $94,162,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IDXX. Opal Wealth Advisors LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $29,000. WealthCollab LLC bought a new position in IDEXX Laboratories in the 2nd quarter worth $30,000. Armstrong Advisory Group Inc. lifted its position in IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after acquiring an additional 19 shares during the last quarter. Ameritas Advisory Services LLC bought a new stake in IDEXX Laboratories during the second quarter valued at about $36,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at about $36,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $682.31 on Wednesday. The firm has a market capitalization of $54.48 billion, a PE ratio of 54.11, a PEG ratio of 4.19 and a beta of 1.67. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The business’s 50 day moving average is $692.65 and its 200-day moving average is $629.36.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the company posted $2.80 earnings per share. IDEXX Laboratories’s revenue was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on IDXX shares. Barclays started coverage on IDEXX Laboratories in a research report on Monday, December 8th. They set an “overweight” rating and a $850.00 price objective for the company. Morgan Stanley lifted their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. UBS Group upped their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. BTIG Research raised their price objective on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 29th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $763.50.

Insider Activity at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.